{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:06:28Z","timestamp":1789693588259,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00512449"],"award-info":[{"award-number":["RS-2024-00512449"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Korea Ministry of Small and Medium Enterprises and Startups","doi-asserted-by":"publisher","award":["RS-2025-25459577"],"award-info":[{"award-number":["RS-2025-25459577"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C2006223"],"award-info":[{"award-number":["2023R1A2C2006223"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00451679"],"award-info":[{"award-number":["RS-2024-00451679"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.007","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:11:45Z","timestamp":1786453905000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment"],"prefix":"10.1016","volume":"212","author":[{"given":"Jun-Hyeong","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurimi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Eun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chel-Hun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.007_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0010","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab+ chemotherapy versus placebo+ chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0015","doi-asserted-by":"crossref","first-page":"36219","DOI":"10.18632\/oncotarget.5283","article-title":"HER2 as a novel therapeutic target for cervical cancer","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis","volume":"16","author":"Itkin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the international endocervical adenocarcinoma criteria and classification","volume":"7","author":"Shi","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-03304-9","article-title":"Discordance in HER2 status in gastro-esophageal adenocarcinomas: a systematic review and meta-analysis","volume":"7","author":"Creemers","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0050","first-page":"410","article-title":"HER2 expression in cervical squamous cell carcinoma: high prevalence of HER2-low\/ultralow and spatiotemporal heterogeneity across tumor evolution, npj Precis","volume":"9","author":"Liu","year":"2025","journal-title":"Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/his.13977","article-title":"Revising the WHO classification: female genital tract tumours","volume":"76","author":"Cree","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","article-title":"Cervical Cancer, version 2.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2026.08.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100148","article-title":"Assessment of HER2 in gastric-type endocervical adenocarcinoma and its prognostic significance","volume":"36","author":"Wang","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.718636","article-title":"Biological adaptations of tumor cells to radiation therapy","volume":"11","author":"Carlos-Reyes","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0095","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1038\/s41598-019-51959-3","article-title":"Anti-tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0105","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.007_bb0110","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:15Z","timestamp":1789692075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S0090825826020998"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}